Prenatal diagnosis of methotrexate embryopathy.

Abstract

BACKGROUND:

Methotrexate is an antineoplastic agent used by obstetrician-gynecologists for termination of early pregnancy. The drug is not always successful and is associated with a known array of malformations.

CASE:

We present a case of a failed pregnancy termination with methotrexate, which resulted in fetal anomalies. Ultrasound revealed absent or markedly shortened long bones, abnormal positioning of the hands, micrognathia, echogenic bowel, and a two-vessel umbilical cord. The patient elected to undergo pregnancy termination, and the ultrasound findings were confirmed at autopsy.

CONCLUSION:

Because of methotrexate's teratogenic potential, follow-up to confirm successful termination is necessary. Ultrasound evaluation of the fetus is indicated if pregnancy termination is unsuccessful.

• Authors: Jeff B Chapa, Judith U Hibbard, Elyse M Weber, Jacques S Abramowicz, Marion S Verp
• Journal: Obstetrics and gynecology (Obstet Gynecol) Vol. 101 Issue 5 Pt 2 Pg. 1104-7 (May 2003) ISSN: 0029-7844 [Print] United States
• PMID: 12738117 (Publication Type: Case Reports, Journal Article)

Chemical References

• Abortifacient Agents, Nonsteroidal
• Methotrexate

Topics

• Abnormalities, Drug-Induced (diagnostic imaging, etiology)
• Abortifacient Agents, Nonsteroidal (adverse effects)
• Abortion, Induced
• Adult
• Female
• Humans
• Methotrexate (adverse effects)
• Pregnancy
• Treatment Failure
• Ultrasonography, Prenatal